Improvement of experimental accelerated atherosclerosis by chondroitin sulphate

Osteoarthritis and Cartilage

Volumn 18, Issue SUPPL. 1, 2010, Pages

  Martinez Calatrava M J ^a   Largo, R ^a   Herrero Beaumont, G ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Arthritis; Atherosclerosis; Chondroitin sulphate; Chronic inflammation; Rabbit model

Indexed keywords

CHONDROITIN SULFATE; CYCLOOXYGENASE 2; CYTOKINE; GLUCOSAMINE SULFATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE SYNTHASE; PROSTAGLANDIN E2; ANTIINFLAMMATORY AGENT;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CHRONIC ARTHRITIS; CLINICAL FEATURE; DISEASE ASSOCIATION; EXPERIMENTAL MODEL; HUMAN; INFLAMMATORY DISEASE; INSULIN RESISTANCE; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RABBIT; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SYNOVITIS; ANIMAL; COMPLICATION; EXPERIMENTAL ARTHRITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; CHONDROITIN SULFATES; HUMANS; OSTEOARTHRITIS; RABBITS;

EID: 77953806444     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2010.01.014     Document Type: Article

References (41)

1. Gabriel S.E., Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 2009, 11:229.
2. Young A., Koduri G., Batley M., Kulinskaya E., Gough A., Norton S., Early Rheumatoid Arthritis Study (ERAS) Group, et al. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford) 2007, 46:350-357.
3. Gabriel S.E., Crowson C.S., Kremers H.M., Doran M.F., Turesson C., O'Fallon W.M., et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 2003, 48:54-58.
4. del Rincón I., Freeman G.L., Haas R.W., O'Leary D.H., Escalante A. Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum 2005, 52:3413-3423.
5. Roman M.J., Devereux R.B., Schwartz J.E., Lockshin M.D., Paget S.A., Davis A., et al. Arterial stiffness in chronic inflammatory diseases. Hypertension 2005, 46:194-199.
6. del Rincón I.D., Williams K., Stern M.P., Freeman G.L., Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001, 44:2737-2745.
7. del Rincón I., O'Leary D.H., Freeman G.L., Escalante A. Acceleration of atherosclerosis during the course of rheumatoid arthritis. Atherosclerosis 2007, 195:354-360.
8. Stamatelopoulos K.S., Kitas G.D., Papamichael C.M., Chryssohoou E., Kyrkou K., Georgiopoulos G., et al. Atherosclerosis in rheumatoid arthritis versus diabetes. A comparative study. Arterioscler Thromb Vasc Biol 2009.
9. Edwards C.J., Syddall H., Goswami R., Goswami P., Dennison E.M., Arden N.K., Hertfordshire Cohort Study Group, et al. The autoantibody rheumatoid factor may be an independent risk factor for ischaemic heart disease in men. Heart 2007, 93:1263-1267.
10. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352:1685-1695.
11. Hällgren R., Berne C. Glucose intolerance in patients with chronic inflammatory diseases is normalized by glucocorticoids. Acta Med Scand 1983, 213:351-355.
12. Vallvé J.C., Paredes S., Girona J., Uliaque K., Ribalta J., Hurt-Camejo E., et al. Tumor necrosis factor-alpha - 1031 T/C polymorphism is associated with smaller and more proatherogenic low density lipoprotein particles in patients with rheumatoid arthritis. J Rheumatol 2008, 35:1697-1703.
13. Lijnen H.R., Alessi M.C., Van Hoef B., Collen D., Juhan-Vague I. On the role of plasminogen activator inhibitor-1 in adipose tissue development and insulin resistance in mice. J Thromb Haemost 2005, 3:1174-1179.
14. Gonzalez-Gay M.A., Gonzalez-Juanatey C., Piñeiro A., Garcia-Porrua C., Testa A., Llorca J. High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol 2005, 32:1219-1223.
15. Ku I.A., Imboden J.B., Hsue P.Y., Ganz P. Rheumatoid arthritis. Circ J 2009, 73:977-985.
16. Cicuttini F.M., Baker J.R., Spector T.D. The association of obesity with osteoarthritis of the hand and knee in women: a twin study. J Rheumatol 1996, 23:1221-1226.
17. Koskinen J., Kähönen M., Viikari J.S., Taittonen L., Laitinen T., Rönnemaa T., et al. Conventional cardiovascular risk factors and metabolic syndrome in predicting carotid intima-media thickness progression in young adults. The cardiovascular risk in young Finns study. Circulation 2009.
18. Jonsson H., Helgadottir G.P., Aspelund T., Eiriksdottir G., Sigurdsson S., Ingvarsson T., et al. Hand osteoarthritis in older women is associated with carotid and coronary atherosclerosis: the AGES - Reykjavik study. Ann Rheum Dis 2008.
19. Findlay D.M. Vascular pathology and osteoarthritis. Rheumatology (Oxford) 2007, 46:1763-1768.
20. Imhof H., Sulzbacher I., Grampp S., Czerny C., Youssefzadeh S., Kainberger F. Subchondral bone and cartilage disease: a rediscovered functional unit. Invest Radiol 2000, 35:581-588.
21. Dodd J.S., Raleigh J.A., Gross T.S. Osteocyte hypoxia: a novel mechanotransduction pathway. Am J Physiol 1999, 277:C598-602.
22. Felson D.T.M.S., Goggins J., LaValley M.P., Gale M.E., Totterman S., Li W., et al. Bone marrow edema and its relation to progression of knee osteoarthritis. Ann Intern Med 2003, 139:330-336.
23. Hunter D.J., Zhang Y., Niu J., Goggins J., Amin S., LaValley M.P., et al. Increase in bone marrow lesions associated with cartilage loss: a longitudinal magnetic resonance imaging study of knee osteoarthritis. Arthritis Rheum 2006, 54:1529-1535.
24. Miller D., Forrester K., Hart D.A., Leonard C., Salo P., Bray R.C. Endothelial dysfunction and decreased vascular responsiveness in the anterior cruciate ligament-deficient model of osteoarthritis. J Appl Physiol 2007, 102:1161-1169.
25. Felson D.T., Lawrence R.C., Dieppe P.A., Hirsch R., Helmick C.G., Jordan J.M., et al. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med 2000, 133:635-646.
26. Breslow J.L. Mouse models of atherosclerosis. Science 1996, 272:685-688.
27. Iacobini C.M.S., Ricci C., Scipioni A., Sansoni V., Cordone S., Taurino M., et al. Accelerated lipid-induced atherogenesis in galectin-3-deficient mice: role of lipoxidation via receptor-mediated mechanisms. Arterioscler Thromb Vasc Biol 2009, 29:831-836.
28. Ma Z., Choudhury A., Kang S.A., Monestier M., Cohen P.L., Eisenberg R.A. Accelerated atherosclerosis in ApoE deficient lupus mouse models. Clin Immunol 2008, 127:168-175.
29. King V.L., Hatch N.W., Chan H.W., de Beer M.C., de Beer F.C., Tannock L.R. A murine model of obesity with accelerated atherosclerosis. Obesity (Silver Spring) 2009.
30. Renard C.B., Kramer F., Johansson F., Lamharzi N., Tannock L.R., von Herrath M.G., et al. Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. J Clin Invest 2004, 114:659-668.
31. Largo R., Sánchez-Pernaute O., Marcos M.E., Moreno-Rubio J., Aparicio C., Granado R., et al. Chronic arthritis aggravates vascular lesions in rabbits with atherosclerosis: a novel model of atherosclerosis associated with chronic inflammation. Arthritis Rheum 2008, 58:2723-2734.
32. Wight T.N., Merrilees M.J. Proteoglycans in atherosclerosis and restenosis. Key roles for versican. Circ Res 2004, 94:1158-1167.
33. Teocharis A.D., Tsolakis I., Tzanakakis G.N., Karamanos N.K. Chondroitin sulfate as a key molecule in the development of atherosclerosis and cancer progression. Adv Pharmacol 2006, 53:281-295.
34. Iovu M., Dumais G., du Souich P. Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage 2008, 16:S14-18.
35. Álvarez-soria M.A., Largo R., Santillana J., Calvo E., Egido J., Herrero-Beaumont G. Differential anticatabolic profile of glucosamine sulfate versus other anti-osteoarthritic drugs on human osteoarthritic drugs on human osteoarthritic drugs on human osteoarthritic chondrocytes and synovial fibroblast in culture. Osteoarthritis Cartilage 2005, 13:S153.
36. du Souich P., Garcia A.G., Verges J., Montell E. Immunomodulatory and anti-inflammatory effects of chondroitin sulphate. J Cell Mol Med 2009.
37. Herrero-Beaumont G., Marcos M.E., Sánchez-Pernaute O., Granados R., Ortega L., Montell E., et al. Effect of chondroitin sulphate in a rabbit model of atherosclerosis aggravated by chronic arthritis. Br J Pharmacol 2008, 154:843-851.
38. Largo R., Alvarez-Soria M.A., Díez-Ortego I., Calvo E., Sánchez-Pernaute O., Egido J., et al. Glucosamine inhibits IL-1beta-induced NFkappaB activation in human osteoarthritic chondrocytes. Osteoarthritis Cartilage 2003, 11:290-298.
39. Rafi M.M., Yadav P.N., Rossi A.O. Glucosamine inhibits LPS-induced COX-2 and iNOS expression in mouse macrophage cells (RAW 264.7) by inhibition of p38-MAP kinase and transcription factor NF-kappaB. Mol Nutr Food Res 2007, 51:587-593.
40. Pham T., Cornea A., Blick K.E., Jenkins A., Scofield R.H. Oral glucosamine in doses used to treat osteoarthritis worsens insulin resistance. Am J Med Sci 2007, 333:333-339.
41. Echard B.W., Talpur N.A., Funk K.A., Bagchi D., Preuss H.G. Effects of oral glucosamine and chondroitin sulfate alone and in combination on the metabolism of SHR and SD rats. Mol Cell Biochem 2001, 225:85-91.